QLT gets neutral rating from Merrill

Merrill Lynch analyst Hari Sambasivam rated QLT Inc. at neutral ahead of the company's third-quarter results. The analyst estimates global Visudyne sales of $87 million, revenues of $41.4 million and pro forma net income of $6.8 million for the quarter. Visudyne sales estimates were revised from $94 million, and in 2006 to $376 million from $383 million, on the strong Lucentis launch. Shares of the Vancouver, B.C.-based biopharmaceutical company were up 8 cents, or 1.03%, at $7.88. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.